The Department of Health and Human Services, Department of Justice, and Federal Trade Commission Dec. 7 announced several new actions to promote competition in health care and support lower prescription drug costs. Among other things, the agencies will seek public input on the impact of private equity and corporate control in health care to identify areas for future regulation and enforcement; improve information sharing to better identify anticompetitive “rollups” that evade antitrust scrutiny; and appoint an HHS chief competition officer and health care chief counsels at DOJ and FTC. 

In addition, the Centers for Medicare & Medicaid Services today released ownership data for Federally Qualified Health Centers and Rural Health Clinics and plans to seek public input early next year to strengthen data and transparency in the Medicare Advantage market, the Administration said. The Department of Commerce and HHS also proposed a framework to promote access to taxpayer-funded inventions, including medical treatments.

Related News Articles

Headline
The Federal Trade Commission and Department of Health and Human Services Feb. 14 requested comments for 60 days on market concentration and contracting…
Headline
The companies that make the first 10 Medicare Part D drugs selected to participate in the Medicare Drug Price Negotiation Program have agreed to participate in…
Headline
The Food and Drug Administration will accept comments through Nov. 17 on draft guidance for labeling proposed biosimilar and interchangeable biosimilar…
Headline
A new Centers for Medicare & Medicaid Services fact sheet reviews how the agency selected the first 10 Part D drugs to include in the Medicare Drug Price…
Headline
The Department of Health and Human Services announced the first list of Medicare Part D drugs subject to price negotiations, a tenet of the Inflation…
Headline
A new study by Business Group on Health reveals that, amid increases in the percentage of health care dollars spent on pharmacy, 92% of employers are…